

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:
DEAV2003/0002 US NPApplicants:
KLINGLER, et al.Serial No.
10/751,545Filing Date:
January 5, 2004Title of Invention:
SELECTIVE MMP-13 INHIBITORS

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at 703 746-9195, onDate of Deposit July 6, 2004Printed Name of Person Signing Certificate Phyllis Renee McHarrisSignature Phyllis Renee McHarris

Total Number of Pages Sent: 10

Attorney: Raymond S. PARKER, III

Group Art Unit: 1614

Examiner:

TO: Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450Please acknowledge receipt of the below-listed documents for the above Application by return telefax to
(908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of
Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Request For Corrected Filing Receipt</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Copy of Filing Receipt</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | <input checked="" type="checkbox"/> Other <u>Supplemental Application Data Sheet - 5 pages</u> |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of
KLINGLER, et al.

Examiner:

Art Unit: 1614

Application No.: **10/751,545**

Filed: **January 5, 2004**

Title: **SELECTIVE MMP-13 INHIBITORS**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,
at (703) 746-9195, on

July 6, 2004
Date of Deposit
Phyllis Rose McGinnis
Signature

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the
above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the First named inventor's name is misspelled. It should appear as
follows: **Otmar KLINGLER.**

There is also an error in the order of inventors. Please list the inventors in the following
order:


Otmar KLINGLER
Reinhard KIRSCH
Joerg HABERMANN
Klaus-Ulrich WEITHMANN
Christian ENGEL
Bernard PIRARD

Also, a supplemental application data sheet is enclosed.

The Commissioner is hereby authorized to charge any fees which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,

July 6, 2004


Raymond S. Parker, III, Ph.D., Reg. No. 34,893
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5674
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0002 US NP



UNITED STATES PATENT AND TRADEMARK OFFICE

COPYUNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/751,545	01/05/2004	1614	770	DEAV20030002USNP		11	1

CONFIRMATION NO. 2394

05487

ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807

FILING RECEIPT

OC000000012325347

RSP / J. THEN
COMPUTER ENTERED
JES 4/15/04

Date Mailed: 04/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)Otmav Klinger, Rodgau, GERMANY;
Reinhard Kirsch, Braunschweig, GERMANY;
Joerg Habermann, Roma, ITALY;
Christian Engel, Frankfurt, GERMANY;
Bernard Pirard, Darmstadt, GERMANY;
Klaus-Ulrich Weithmann, Hofheim, GERMANY;**Assignment For Published Patent Application**

AVENTIS PHARMA DEUTSCHLAND GMBH, Frankfurt am Main, GERMANY;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/472,765 05/22/2003

Foreign Applications

GERMANY 10300017.8 01/03/2003

If Required, Foreign Filing License Granted: 04/09/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Selective MMP-13 inhibitors

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).